Medication classified as a generic has the same active component as a branded drug. The therapeutic effects of these medications are same, and they are prescribed with the same dosage, quality, and usage patterns. However, compared to their branded counterparts, generic medications' inactive components can vary. These medications are primarily marketed after a branded drug's patent expires and are much less expensive than the patented branded drugs. Generic drugs are manufactured using the same safety and manufacturing practices as branded pharmaceuticals and are of comparable quality. Following the expiration of patent exclusivity, some manufacturers submit an abbreviated new drug application (ANDA) to the FDA.
Generic drug makers are focused on the development and introduction of innovative medications and formulations, such as biosimilars. When a drug's patent expires, many market players should be able to develop the generic counterpart. Furthermore, the FDA's attempt to aid in the development of biosimilars is encouraging companies to give it their full attention. Other reasons driving the growth of the generic pharmaceuticals market include an increase in the prevalence of chronic diseases. However, a lack of active pharmaceutical components is causing generics to be unavailable in the market, and increased FDA pressure on manufacturers to improve the manufacturing quality of these pharmaceuticals is impeding market growth.
Top Companies in the Generic Drugs Industry:
1. Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is an Israeli multinational pharmaceutical company. It was founded in 1901 and headquartered in Tel Aviv, Israel.. It operates in more than 60 countries. In order to position the business for a new era of growth, Teva Pharmaceutical Industries Ltd. adopted a new strategy framework with four main pillars in May 2023. With AUSTEDO®, AJOVY®, UZEDYTM, and biosimilars, this approach aims to bolster the company's robust commercial portfolio, increase its innovative pipeline, keep the company's generics powerhouse, and focus the business. These four pillars are seen to be more beneficial and to have a bigger impact on patients.
2. Mylan N.V.
Mylan N.V. was a global generic and specialty pharmaceuticals company. It was founded in 1961 and headquartered in Pennsylvania, United States. It operates in more than 165 countries and territories. In November 16, 2020 ,Mylan gives way to Viatris after nearly 60 years. With its merger with the Upjohn division of Pfizer Inc., the Canonsburg-based company has relaunched. In July 2019, combining Mylan with Upjohn, two Pfizer divisions, created a new champion for global health that is specially positioned to meet the demand for medicine around the world.